clinical trial · NCT05506943
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract CancerCholangiocarcinomaGall Bladder CancerAmpullary CancerCTX-009Paclitaxel
brief summary
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
started
Jan 9, 2023
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
May 7, 2026
official title
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol